12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Other News

Endo, U.S. Food and Drug Administration neurology news

Endo said a judge in the U.S. District Court for the District of Columbia dismissed the company's suit seeking to force FDA to determine in "a timely fashion" if the company withdrew the original, non-crush resistant formulation of pain drug Opana ER oxymorphone due to safety reasons. FDA is required by law to withdraw or...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >